Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US

Antiviral Therapy

Volumn 20, Issue 1, 2015, Pages 21-28

  Jarrin, Inma ^a   Moreno, Santiago ^a   Ingle, Sue ^a   May, Margaret T ^a   Sterling, Timothy R ^a   Justice, Amy ^a   Bickel, Markus ^a   Crane, Heidi ^a   Mugavero, Michael J ^a   De Wolf, Frank ^a   Jung, Norma ^a   Cescon, Angela ^a   Garcia, Isabel ^a   Elzi, Luigia ^a   D'Arminio, Antonella ^a   Mary Krause, Murielle ^a   Smith, Colette ^a   Guest, Jodie ^a   Hessamfar, Mojgan ^a   Gill, John ^a   Sterne, Jonathan A C ^a   Del Amo, Julia ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CAUSE SPECIFIC MORTALITY; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIVER DISEASE; LUNG DISEASE; MALE; MORTALITY; NEOPLASM; OVERALL MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE; SEX RATIO; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SUBSTANCE ABUSE; UNITED STATES; VIRUS TRANSMISSION; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER DISEASES; MIDDLE AGED; NEOPLASMS; PHYSIOLOGY; RISK FACTOR; SURVIVAL; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; UNITED STATES; VIRAL LOAD;

EID: 84927724609     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2768     Document Type: Article

References (31)

1. Waldron I. Recent trends in sex mortality ratios for adults in developed countries. Soc Sci Med 1993; 36:451-462.
2. Gjonça A, Tomassini C, Toson B, Smallwood S. Sex differences in mortality, a comparison of the United Kingdom and other developed countries. Health Stat Q 2005; 26:6-16.
3. Oksuzyan A, Crimmins E, Saito Y, O'Rand A, Vaupel JW, Christensen K. Cross-national comparison of sex differences in health and mortality in Denmark, Japan and the US. Eur J Epidemiol 2010; 25:471-480.
4. Barford A, Dorling D, Smith D, Shaw M. Life expectancy: women now on top everywhere. BMJ 2006; 332:808.
5. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
6. Mocroft A, Lederberger B, Katlama C, et al. Decline in the AIDS death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
7. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
8. Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15:1115-1123.
9. Hessol NA, Kalinowski A, Benning L, et al. Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 2007; 44:287-294.
10. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 2009; 199:991-998.
11. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24:475-482.
12. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008; 168:532-540.
13. García de la Hera M, Ferreros I, del Amo J, et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 2004; 58:944-950.
14. Pérez-Hoyos S, del Amo J, Muga R, et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17:353-359.
15. Porter K, Babiker A, Bhaskaran K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
16. Pezzotti P, Dorrucci M, Donisi A, et al. Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART). Epidemiol Prev 2003; 27:348-355.
17. Johnson L F, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013; 10:e1001418.
18. Egger M, May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
19. May MT, Ingle SM, Costagliola D, et al. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol 2013; 43:691-702.
20. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
21. Fine J P, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
22. Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. Br Med Bull 2009; 92:7-32.
23. Pampel F. Forecasting sex differences in mortality in high income nations: the contribution of smoking. Demogr Res 2005; 13:455-484.
24. Del Amo J, Likatavicius G, Perez-Cachafeiro S, et al. The epidemiology of HIV and AIDS reports in migrants in the 27 European Union countries, Norway and Iceland: 1999-2006. Eur J Public Health 2011; 21:620-626.
25. Jarrin I, Pantazis N, Gill MJ, et al. CASCADE Collaboration in EuroCoord. Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clin Infect Dis 2012; 54:111-118.
26. The Antiretroviral Therapy Cohort Collaboration (ART-CC). Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States. Clin Infect Dis 2013; 56:1800-1809.
27. Martin LJ, Houston S, Yasui Y, Wild TC, Saunders LD. All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use. Can J Public Health 2011; 102:90-96.
28. Oramasionwu CU, Brown CM, Lawson KA, Ryan L, Frei CR. Evaluating HIV/AIDS disparities for blacks in the United States: a review of antiretroviral and mortality studies. J Natl Med Assoc 2009; 101:1221-1229.
29. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009; 51:399-406.
30. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health 2006; 96:1060-1065.
31. May MT, Hogg RS, Justice AC, et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol 2012; 41:1807-1820.